Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phosphoproteomic prediction of kinase inhibitor response in advanced renal cell cancer
NL-OMON26770Recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Nov 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of sunitinib, pazopanib, sorafenib, axitinib and everolimus in renal cell carcinoma (RCC) (5 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Pretreatment tumor phosphoproteomic profile versus treatment outcome. Started Nov 2012; status: recruiting.
02
Drugs
sunitinibpazopanibsorafenibaxitinibeverolimus
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NL-OMON26770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON26770.